论文部分内容阅读
非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)是慢性肝病的常见病因,非酒精性脂肪性肝炎(nonalcoholic steatohepatitis,NASH)是NAFLD的进展形式,与肝病相关病死率和心血管疾病风险增加相关。当前,肝活检是惟一被临床广泛接受的诊断方法,可评估NASH向肝硬化进展。对NASH患者尚无确证的非创伤性诊断方法和公认的治疗措施。本文在总结2009年美国肝病学会对NASH特定临床试验设计和关键性治疗终点并达成一致共
Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease. Nonalcoholic steatohepatitis (NASH) is a form of progression of NAFLD with an increased risk of liver-related mortality and cardiovascular disease Related. Currently, liver biopsy is the only clinically widely accepted diagnostic method to assess the progression of NASH to cirrhosis. There is no definitive non-invasive diagnostic method and accepted treatment for NASH patients. This article summarizes the 2009 American College of Hepatology NASH-specific clinical trial design and key treatment endpoint and reached a consensus